Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.

Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M.

Br J Haematol. 2019 Mar;184(5):735-743. doi: 10.1111/bjh.15700. Epub 2018 Dec 12.

PMID:
30548250
2.

Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.

Bonilla-Valentín FJ, Cerra J, Cáceres-Perkins W, Alsina M.

Cancer Control. 2018 Jan-Mar;25(1):1073274817744448. doi: 10.1177/1073274817744448.

3.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
4.

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J.

Br J Haematol. 2018 Jan;180(2):271-275. doi: 10.1111/bjh.14970. Epub 2017 Oct 19.

PMID:
29048105
5.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):400-405. doi: 10.1016/j.bbmt.2017.09.022. Epub 2017 Oct 13.

6.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
7.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C.

Haematologica. 2017 May;102(5):948-957. doi: 10.3324/haematol.2016.153072. Epub 2017 Jan 19.

8.

Deacetylase inhibitors: an advance in myeloma therapy?

Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG.

Expert Rev Hematol. 2017 Mar;10(3):229-237. doi: 10.1080/17474086.2017.1280388. Epub 2017 Feb 1. Review.

PMID:
28076695
9.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
10.

Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.

Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH.

Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.

PMID:
27424609
11.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

12.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.

13.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

14.

Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.

Salem KZ, Nishihori T, Kharfan-Dabaja MA, Horna P, Alsina M.

Hematol Oncol Stem Cell Ther. 2016 Mar;9(1):26-9. doi: 10.1016/j.hemonc.2015.06.007. Epub 2015 Jul 8.

15.

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.

Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC.

Cancer. 2015 Oct 15;121(20):3622-30. doi: 10.1002/cncr.29533. Epub 2015 Jul 6.

16.

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.

Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF.

Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Review. Erratum in: Expert Rev Anticancer Ther. 2015;15(9):1121.

PMID:
26051506
17.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588. Epub 2015 Apr 3.

18.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1074-82. doi: 10.1016/j.bbmt.2015.03.014. Epub 2015 Mar 21.

19.

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M.

Eur J Haematol. 2015 Nov;95(5):426-35. doi: 10.1111/ejh.12509. Epub 2015 Mar 12.

20.

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC; Resource for Clinical Investigation in Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1183-9. doi: 10.1016/j.bbmt.2014.04.014. Epub 2014 Apr 21.

21.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.

Blood. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15.

22.

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M.

Am J Hematol. 2014 Jan;89(1):62-7. doi: 10.1002/ajh.23587.

23.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R.

Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6.

24.

Immunotherapy strategies for multiple myeloma: the present and the future.

Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA.

Immunotherapy. 2013 Sep;5(9):1005-20. doi: 10.2217/imt.13.97. Review.

25.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
26.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S.

Blood. 2013 Oct 3;122(14):2331-7. doi: 10.1182/blood-2013-01-481325. Epub 2013 Aug 15.

27.

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B.

Leuk Res. 2013 Sep;37(9):1077-82. doi: 10.1016/j.leukres.2013.06.005. Epub 2013 Jun 25.

PMID:
23809054
28.

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1087-93. doi: 10.1016/j.bbmt.2013.04.020. Epub 2013 Apr 28.

29.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Niesvizky R, Martin TG 3rd, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M.

Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27.

30.

Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.

Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1144-51. doi: 10.1016/j.bbmt.2013.02.003. Epub 2013 Feb 13. Review.

31.

Multiple myeloma, version 1.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.

PMID:
23307977
32.

Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?

Alayón-Laguer D, Alsina M, Ochoa-Bayona JL, Ayala E.

Case Rep Transplant. 2012;2012:942795. doi: 10.1155/2012/942795. Epub 2012 May 7.

33.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.

Blood. 2013 Mar 14;121(11):1961-7. doi: 10.1182/blood-2012-08-450742. Epub 2012 Dec 14.

34.

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR.

Drug Metab Dispos. 2013 Jan;41(1):230-7. doi: 10.1124/dmd.112.047662. Epub 2012 Nov 1.

PMID:
23118326
35.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network).

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9.

PMID:
23054875
36.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC.

Blood. 2012 Nov 29;120(23):4513-6. doi: 10.1182/blood-2012-05-426924. Epub 2012 Sep 27.

37.

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE.

Clin Cancer Res. 2012 Nov 15;18(22):6155-68. doi: 10.1158/1078-0432.CCR-12-0531. Epub 2012 Sep 17.

38.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S.

Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.

39.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A.

Clin Cancer Res. 2012 Sep 1;18(17):4830-40. Epub 2012 Jul 3.

40.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C.

Haematologica. 2012 Dec;97(12):1882-9. doi: 10.3324/haematol.2012.067140. Epub 2012 Jun 11.

41.

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.

Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC.

Br J Haematol. 2012 Aug;158(4):472-80. doi: 10.1111/j.1365-2141.2012.09173.x. Epub 2012 May 29.

42.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

43.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M.

Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26.

44.

Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.

Nishihori T, Alsina M.

Cancer Control. 2011 Oct;18(4):258-67. Review.

PMID:
21976244
45.

Multiple myeloma.

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Oct;9(10):1146-83. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Dec 1;9(12):xxv.

PMID:
21975914
46.

Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-11. doi: 10.1016/j.clml.2011.06.010. Epub 2011 Aug 2.

PMID:
21813352
47.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].

48.

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.

Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C.

Haematologica. 2011 Sep;96(9):1351-6. doi: 10.3324/haematol.2011.041236. Epub 2011 May 12.

49.

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol. 2011 Jun;153(6):729-40. doi: 10.1111/j.1365-2141.2011.08664.x. Epub 2011 Apr 28.

PMID:
21534941
50.

Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.

Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1505-11. doi: 10.1016/j.bbmt.2011.02.011. Epub 2011 Mar 6.

Supplemental Content

Loading ...
Support Center